Gefitinib: Targeted Therapy for Advanced Lung Cancer

daisymiller

Gefitinib is a targeted cancer therapy used primarily to treat non-small cell lung cancer (NSCLC) that is positive for epidermal growth factor receptor (EGFR) mutations. As an EGFR tyrosine kinase inhibitor, Gefitinib works by blocking the signals that promote cancer cell growth and survival. This precision mechanism makes it especially effective in patients with specific genetic profiles, offering improved response rates and better quality of life compared to traditional chemotherapy.

Taken orally, Gefitinib is often preferred for its convenience and lower toxicity. It is particularly beneficial in patients with advanced or metastatic NSCLC who have shown sensitivity to EGFR-targeted treatments. The drug can significantly delay disease progression and has become a standard first-line treatment in many countries.

With lung cancer being one of the leading causes of cancer deaths worldwide, ensuring timely access to effective drugs like Gefitinib is critical. Gefitinib India manufacturer play a key role in making this life-saving medication more affordable and accessible. By producing high-quality, cost-effective generics, Indian pharmaceutical companies support global cancer care efforts and improve treatment availability in both developed and developing nations. Their contribution is vital in meeting the growing global demand for advanced oncology therapies.